Outcomes associated with trimethoprim/sulphamethoxazole (TMP/SMX) therapy in TMP/SMX resistant community-acquired UTI

被引：43

作者：

Gupta, K ^{[1
]}

Stamm, WE ^{[1
]}

机构：

[1] Univ Washington, Seattle, WA 98195 USA

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2002年 / 19卷 / 06期

关键词：

trimethoprim/sulphamethoxazole (TMP/SMX) therapy; UTI; Escherichia coli;

D O I：

10.1016/S0924-8579(02)00104-8

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The increase in resistance rates to TMP/SMX among E coli causing community-acquired UTI has resulted in consideration of alternative agents as first line therapy for these infections. However, there has been little study of the clinical significance of the in vitro trends in resistance which have been reported. We review studies that address the correlation between in vitro resistance to TMP/SMX and clinical outcome in uncomplicated UTI. From these data, it is clear that in vitro resistance does translate into therapeutic failure for 50-60% of patients with a TMP/SMX resistant uropathogen. Thus, it is reasonable to consider an agent other than TMP/SMX when the TMP/SMX resistance prevalence reaches 20%. (C) 2002 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.

引用

收藏

页码：554 / 556

页数：3

相关论文

共 13 条

[1]

Dyer IE, 1998, WESTERN J MED, V169, P265

[2] Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women [J].

Gupta, K ;

Scholes, U ;

Stamm, WE .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (08) :736-738

[3] Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections [J].

Gupta, K ;

Hooton, TM ;

Stamm, WE .

ANNALS OF INTERNAL MEDICINE, 2001, 135 (01) :41-50

[4] Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: A nationwide analysis [J].

Gupta, K ;

Sahm, DF ;

Mayfield, D ;

Stamm, WE .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (01) :89-94

[5] Diagnosis and treatment of uncomplicated urinary tract infection [J].

Hooton, TM ;

Stamm, WE .

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 1997, 11 (03) :551-+

[6] Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999 [J].

Karlowsky, JA ;

Jones, ME ;

Thornsberry, C ;

Critchley, I ;

Kelly, LJ ;

Sahm, DF .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 18 (02) :121-127

[7] Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: A decision and cost analysis [J].

Le, TP ;

Miller, LG .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (05) :615-621

[8] HIGH-DOSAGE CO-AMOXICLAV IN A SINGLE-DOSE VERSUS 7 DAYS OF COTRIMOXAZOLE AS TREATMENT OF UNCOMPLICATED LOWER URINARY-TRACT INFECTION IN WOMEN [J].

MASTERTON, RG ;

BOCHSLER, JA .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 35 (01) :129-137

[9] A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women [J].

McCarthy, JM ;

Richard, G ;

Huck, W ;

Tucker, RM ;

Tosiello, RL ;

Shan, M ;

Heyd, A ;

Echols, RM .

AMERICAN JOURNAL OF MEDICINE, 1999, 106 (03) :292-299

[10] Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens [J].

Raz, R ;

Chazan, B ;

Kennes, Y ;

Colodner, R ;

Rottensterich, E ;

Dan, M ;

Lavi, I ;

Stamm, W .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (09) :1165-1169